# Edaravone Dexborneol Sublingual Tablet for the PSCI in Acute Ischemic Stroke Patients

> **NCT06315231** · PHASE2 · RECRUITING · sponsor: **Simcere Pharmaceutical Co., Ltd** · enrollment: 226 (estimated)

## Conditions studied

- Post-stroke Cognitive Impairment

## Interventions

- **DRUG:** Edaravone dexborneol sublingual tablet
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06315231
- **Lead sponsor:** Simcere Pharmaceutical Co., Ltd
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-04-08
- **Primary completion:** 2026-12-30
- **Final completion:** 2026-12-30
- **Target enrollment:** 226 (ESTIMATED)
- **Last updated:** 2025-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06315231

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06315231, "Edaravone Dexborneol Sublingual Tablet for the PSCI in Acute Ischemic Stroke Patients". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT06315231. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*